Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Editas Medicine
Biotech
JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend
The flood of licensing deals and M&A may have slowed, but there's still plenty of action to come.
Annalee Armstrong
,
Gabrielle Masson
,
James Waldron
,
Max Bayer
,
Ben Adams
Jan 10, 2024 4:38pm
Vertex pays Editas $100M to use gene-editing tech
Dec 13, 2023 12:46pm
ASH: Editas shares data for mid-stage sickle cell disease asset
Dec 11, 2023 2:33pm
Sanofi finds new R&D head—Chutes & Ladders
Sep 1, 2023 9:30am
Pfizer exec out the door—Chutes & Ladders
Jul 28, 2023 9:30am
Editas posts early sickle cell data as it races to catch Vertex
Jun 9, 2023 5:00am